Litigation Details for Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)
✉ Email this page to a colleague
Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-01-17 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2018-05-02 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 8,859,623 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 0000-00-00 | 25 | Response/Opposition to a Motion or Petition | Paragon’s application issued as U.S. Patent No. 8,859,623 in October 2014, and it does not expire…immediate threat of a patent infringement suit on the ’623 patent. The Patent Office instituted …the Patent Office’s decision here will have in future patent infringement litigation. The Patent Act …APPEAL FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE, PATENT TRIAL AND APPEAL BOARD IN…address the new patent application filing” by Paragon that eventually became the ’623 patent. Ex. 1 ¶ 9; | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
